ATA901688A - Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel - Google Patents

Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel

Info

Publication number
ATA901688A
ATA901688A AT0901688A AT901688A ATA901688A AT A901688 A ATA901688 A AT A901688A AT 0901688 A AT0901688 A AT 0901688A AT 901688 A AT901688 A AT 901688A AT A901688 A ATA901688 A AT A901688A
Authority
AT
Austria
Prior art keywords
cyanoprostacycline
cyclodextrinclathrate
derivatives
medicinal product
medicinal
Prior art date
Application number
AT0901688A
Other languages
English (en)
Other versions
AT396687B (de
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ATA901688A publication Critical patent/ATA901688A/de
Application granted granted Critical
Publication of AT396687B publication Critical patent/AT396687B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT0901688A 1987-11-27 1988-11-25 Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel AT396687B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873740838 DE3740838A1 (de) 1987-11-27 1987-11-27 Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
ATA901688A true ATA901688A (de) 1993-03-15
AT396687B AT396687B (de) 1993-11-25

Family

ID=6341738

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0901688A AT396687B (de) 1987-11-27 1988-11-25 Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel

Country Status (11)

Country Link
US (1) US5010065A (de)
EP (1) EP0349621A1 (de)
JP (1) JPH02502379A (de)
AT (1) AT396687B (de)
BE (1) BE1001327A3 (de)
CH (1) CH677790A5 (de)
DE (1) DE3740838A1 (de)
FR (1) FR2623807B1 (de)
GB (1) GB2231045B (de)
IT (1) IT1227576B (de)
WO (1) WO1989004828A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
DE4104607A1 (de) * 1991-02-12 1992-08-13 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von fiebrigen erkrankungen
DE4135193C1 (de) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5694021A (en) * 1994-02-28 1997-12-02 Kabushiki Kaisha Toshiba System for executing charge control of a secondary battery and detecting the capacitance thereof
US5896596A (en) * 1997-10-22 1999-04-27 Nitto Kogyo Co., Ltd. Apparatus for generating massaging water stream
EP2043629A1 (de) * 2006-07-18 2009-04-08 Bayer Schering Pharma Aktiengesellschaft 5-cyano-prostacyclin-derivate als mittel zur behandlung von autoimmunkrankheiten
JP5271272B2 (ja) 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
JP2013508282A (ja) 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
EP3492106B1 (de) 2013-08-09 2021-02-17 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
EP3972599B1 (de) 2019-05-21 2025-10-22 Ardelyx, Inc. Kombination zur senkung des serum-phosphatspiegels bei einem patienten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (de) * 1970-06-10 1975-02-04
DE2405146A1 (de) * 1974-01-31 1975-08-07 Siemens Ag Mengenmessgeraet mit einem in einer kammer angeordneten rotor
HU179141B (de) * 1977-09-23 1982-08-28
DE2753244A1 (de) * 1977-11-25 1979-06-07 Schering Ag Neue prostacyclinderivate und verfahren zu ihrer herstellung
GB2017699B (en) * 1978-03-31 1983-01-12 Ono Pharmaceutical Co 6,9-methano-pgi2 analogues
JPS5540923A (en) * 1978-09-14 1980-03-22 Ono Sokki Co Ltd Flow meter
JPS56150039A (en) * 1980-04-22 1981-11-20 Sankyo Co Ltd Clathrate compound of prostacycline derivative
DE3427797A1 (de) * 1984-07-25 1986-02-06 Schering AG, 1000 Berlin und 4709 Bergkamen Zytoprotektive wirkung von prostacyclin-derivaten an leber, bauchspeicheldruese und niere
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten

Also Published As

Publication number Publication date
GB2231045A (en) 1990-11-07
IT8822760A0 (it) 1988-11-28
WO1989004828A1 (fr) 1989-06-01
GB2231045B (en) 1992-04-29
IT1227576B (it) 1991-04-16
AT396687B (de) 1993-11-25
GB8916355D0 (en) 1990-07-04
FR2623807A1 (fr) 1989-06-02
DE3740838A1 (de) 1989-06-08
BE1001327A3 (fr) 1989-09-26
US5010065A (en) 1991-04-23
EP0349621A1 (de) 1990-01-10
JPH02502379A (ja) 1990-08-02
CH677790A5 (de) 1991-06-28
FR2623807B1 (fr) 1990-08-31

Similar Documents

Publication Publication Date Title
DE3770085D1 (de) Cyclodextrinclathrate von carbacyclinderivaten und ihre verwendung als arzneimittel.
DE68929361D1 (de) Oligoribonukleotid-Derivate und Verwendung davon als Antiviral Arzneimittel
ATA98488A (de) Pharmazeutische verwendung von 17-ketosteroiden
NZ220120A (en) Heterocyclic benzamide derivatives and pharmaceutical composistions
ATA900296A (de) Verwendung von n-glyoxylprolylesterverbindungen in arzneimitteln
KR890701675A (ko) 포장의 개선 및 그 관련재료
DE68914029D1 (de) Arylmethylenderivate von Thiazolidinonen, Imidazolidinonen und Oxazolidininonen, nützlich als antiallergische Wirkstoffe und antiinflammatorische Wirkstoffe.
DE3765270D1 (de) N-alpha-substituierte derivate von n-alpha-arylsulfonylaminoacyl-p-amidinophenylalaninamiden, deren herstellung, deren verwendung als arzneimittel und deren zwischenverbindungen.
DE3785684D1 (de) Pyrrolidinamid-derivate von acylaminosaeure, pharmazeutische zusammensetzung und verwendung.
NO964758D0 (no) Anvendelse av von Willebrand-faktor og farmasöytiske preparater
DE69033636D1 (de) Verwendung von 4-Acyloxychinolin-Derivate als Insektizide und Akarizide
DE3784695D1 (de) Gebrauch von gramineenextrakten als arzneimittel.
DE69726007D1 (de) Prodrogs und analoga von camptothecin und deren verwendung als arzneimittel
KR910700046A (ko) 포르피린의 생산 및 용도
ATE68186T1 (de) Verwendung von podophyllotoxin und dessen derivaten.
ATA262587A (de) Neue naphthalinderivate und sie enthaltende pharmazeutika
DE3866737D1 (de) Bisphosphonsaeure-derivate und sie enthaltende arzneimittel.
ATA901688A (de) Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel
NO884566L (no) Anvendelse av fluorderivater og kontrastpreparat for diagnostisering av ondartede neoplasmer.
DE69329933D1 (de) 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
NO890661D0 (no) Fremstilling av antihyperkolesteroltetrazolforbindelser og mellomprodukter derav.
DK95489D0 (da) Anvendelse af quinolizin- og quinolizinonderivater til fremstilling af et laegemiddel
ATA30594A (de) Gereinigte form von streptograminen, ihre herstellung und sie enthaltende pharmazeutische massen
DE68919154D1 (de) Benzodiazepinverbindungen und ihre Verwendung als Arzneimittel.
ATE9093T1 (de) Benzodiazepinderivate und ihre verwendung als arzneimittel.

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee